Video Tag: multiple sclerosis

Regenerative medicine for the treatment of MS | Behind the Bench with Luke Lairson

Multiple sclerosis (MS) is a debilitating autoimmune disease that disrupts the central nervous system, causing symptoms like muscle weakness, cognitive challenges and a gradual loss of function that current treatments cannot fully repair. MS arises when the immune system attacks the myelin sheath, the protective layer insulating neurons. Scripps Research chemistry professor Luke Lairson discusses his research on the body’s natural repair pathways—specifically those that activate endogenous stem cells to restore myelin. His work aims to develop therapies that complement existing therapeutic approaches and halt MS progression.

Regenerative medicine for the treatment of MS: Enhancing repair to prevent progression

Multiple sclerosis (MS) is a debilitating autoimmune disease that disrupts the central nervous system, causing symptoms like muscle weakness, cognitive challenges and a gradual loss of function that current treatments cannot fully repair. MS arises when the immune system attacks the myelin sheath, the protective layer insulating neurons. In this Front Row lecture, Scripps Research chemistry professor Luke Lairson discussed his research on the body’s natural repair pathways—specifically those that activate endogenous stem cells to restore myelin. His work aims to develop therapies that complement existing therapeutic approaches and halt MS progression.

Front Row spotlight with Luke Lairson

Multiple sclerosis (MS) is a debilitating autoimmune disease that disrupts the central nervous system, causing symptoms like muscle weakness, cognitive challenges and a gradual loss of function that current treatments cannot fully repair. MS arises when the immune system attacks the myelin sheath, the protective layer insulating neurons. Scripps Research chemistry professor Luke Lairson will discuss his research on the body’s natural repair pathways—specifically those that activate endogenous stem cells to restore myelin. His work aims to develop therapies that complement existing therapeutic approaches and halt MS progression.

An engine for new medicines: A century of science changing life

Calibr, a nonprofit research institute founded by Scripps Research President and CEO Pete Schultz, joined Scripps Research in 2018 as its drug discovery division. As a world-class nonprofit “bench to bedside” drug discovery engine, Calibr delivers groundbreaking solutions to unmet medical needs by uniting the creativity of fundamental discovery with highly focused R&D capabilities and expertise.